Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?
01:09pm, Thursday, 01'st Sep 2022
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News
05:22pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
03:31pm, Monday, 29'th Aug 2022 Zacks Investment Research
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
12:47pm, Monday, 29'th Aug 2022
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Incyte to Present at Upcoming Investor Conference
08:00am, Tuesday, 23'rd Aug 2022
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m.
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
04:00pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
4 Growth Stocks to Buy and Hold Forever
10:20am, Friday, 12'th Aug 2022 The Motley Fool
Some businesses are just bigger than any economic headwind and don't run the risk of obsolescence.
4 Growth Stocks to Buy and Hold Forever
06:20am, Friday, 12'th Aug 2022
Some businesses are just bigger than any economic headwind and don't run the risk of obsolescence.
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
02:38pm, Wednesday, 03'rd Aug 2022 Benzinga
Upgrades
Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
03:47pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
12:50pm, Tuesday, 02'nd Aug 2022
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Incyte (INCY) Q2 Earnings and Revenues Surpass Estimates
12:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled
11:54am, Tuesday, 02'nd Aug 2022
Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations. The post Incyte Posts Strong Quarter For Cancer Drug; Here's Why
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2022 Results - Earnings Call Transcript
11:49am, Tuesday, 02'nd Aug 2022
Incyte Corporation (NASDAQ:INCY ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Christine Chiou – Head of Investor Relations Hervé Hoppenot – Chairman, President
Incyte (INCY) Q2 Earnings and Revenues Surpass Estimates
09:50am, Tuesday, 02'nd Aug 2022
Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
